It has been shown in preclinical studies in a mouse model that the use of inhibitory antibodies to TIGIT can improve the antitumor effect of monoclonal antibodies against HER2-positive breast cancer cell lines either alone or in combination with PD1/PD-L1 inhibitors by increasing NK cell infiltration [225]. This evidence concerns the gene ERBB2 and breast carcinoma.